Innovotech Inc. has announced its intention to obtain a stock quotation on the OTCQB Venture Market, an over-the-counter market in the United States. This strategic move aims to enhance the company's visibility within the U.S. investment community, making its shares more accessible to both retail and institutional investors and potentially increasing trading liquidity.
The OTCQB quotation will operate alongside Innovotech's primary listing on the TSX Venture Exchange in Canada. The company expects no significant additional compliance or reporting burdens from this parallel listing. As a foreign private issuer, Innovotech will continue to meet its existing disclosure obligations through SEDAR+, which satisfies OTC market requirements under established exemptions for foreign issuers. Admission to the OTCQB requires companies to meet specific financial standards, maintain current reporting, and undergo an annual verification and management certification process.
In conjunction with the OTCQB application, Innovotech will also seek eligibility with the Depository Trust Company (DTC). This step is crucial as it would enable simplified electronic clearing and settlement of the company's common shares for investors based in the United States, streamlining the investment process.
Innovotech Inc. is a Canadian boutique contract research organization that specializes in advanced laboratory services and commercializing proprietary technologies. The company is a leader in biofilm science, providing expertise in antimicrobial testing, pharmaceutical analysis, and industrial laboratory solutions. Its services are supported by innovative methodologies and products, including its widely-used MBEC Assay® kit for high-throughput antimicrobial and antibiotic testing. The company serves clients across multiple sectors, delivering customized research and testing services designed to meet rigorous regulatory and scientific standards, such as those of the U.S. Food and Drug Administration and Health Canada, through its ISO-certified and GMP-accredited laboratories. More information is available at https://www.innovotech.ca.
The announcement contains forward-looking statements that are subject to various risks and uncertainties. Factors that could cause actual results to differ include the regulatory environment, currency fluctuations, reliance on a small number of customers including government organizations, fluctuations in operating results, government policies, progress and costs of clinical trials, reliance on key strategic relationships, intellectual property protection issues, and exposure to litigation. The company undertakes no obligation to update these statements except as required by law. The original release can be viewed on www.newmediawire.com.
For business and technology leaders, this development highlights a growing trend of cross-border financial market integration, particularly for specialized technology and life sciences firms seeking broader capital access. The move could signal Innovotech's growth ambitions and its strategy to tap into the larger U.S. investor base, potentially influencing similar companies considering international market expansions. Increased liquidity and visibility often correlate with enhanced valuation opportunities and greater stability for shareholders, making this a significant step for the company's financial strategy.
